Carregant...
ENGAGE and EMERGE: Truth and consequences?
The potential benefit of the anti‐amyloid drug aducanumab based on results of recent EMERGE and ENGAGE clinical trials has generated great controversy and has very important implications for the future of anti‐amyloid drug therapies. The two trials of 18‐month duration were done in patients with mil...
Guardat en:
| Publicat a: | Alzheimers Dement |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8248059/ https://ncbi.nlm.nih.gov/pubmed/33656288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/alz.12286 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|